A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: A subdivision of the original high-risk group on the basis of outcome

Surgery

Volumn 141, Issue 6, 2007, Pages 748-756

  Huang, Hsuan Ying ^a   Li, Chien Feng ^b   Huang, Wen Wei ^c   Hu, Tsung Hui ^a   Lin, Ching Nan ^b   Uen, Yih Huei ^b   Hsiung, Ching Yeh ^a   Lu, David ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHI MEI FOUNDATION HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETHALITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CODING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONSENSUS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 34249788442     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.01.024     Document Type: Article

References (38)

1. Miettinen M., El-Rifai W., and Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. L HLS. Hum Pathol 33 (2002) 478-483
2. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
3. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
4. Martin J., Poveda A., Llombart-Bosch A., Ramos R., Lopez-Guerrero J.A., Garcia del Muro J., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 (2005) 6190-6198
5. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
6. Hirota S., Ohashi A., Nishida T., Isozaki K., Kinoshita K., Shinomura Y., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125 (2003) 660-667
7. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
8. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 (2002) 1692-1703
9. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
10. Dagher R., Cohen M., Williams G., Rothmann M., Gobburu J., Robbie G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8 (2002) 3034-3038
11. Emory T.S., Sobin L.H., Lukes L., Lee D.H., and O'Leary T.J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23 (1999) 82-87
12. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
13. Li C.F., Chuang S.S., Lu C.L., and Lin C.N. Gastrointestinal stromal tumor (GIST) in southern Taiwan: a clinicopathologic study of 93 resected cases. Pathol Res Pract 201 (2005) 1-9
14. Benjamin R.S., Blanke C.D., Blay J.Y., Bonvalot S., and Eisenberg B. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist 11 (2006) 9-20
15. Blay J.Y., Bonvalot S., Casali P., Choi H., Debiec-Richter M., Dei Tos A.P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 (2005) 566-578
16. van der Zwan S.M., and DeMatteo R.P. Gastrointestinal stromal tumor: 5 years later. Cancer 104 (2005) 1781-1788
17. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
18. Chen L.L., Trent J.C., Wu E.F., Fuller G.N., Ramdas L., Zhang W., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64 (2004) 5913-5919
19. Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
20. Trupiano J.K., Stewart R.E., Misick C., Appelman H.D., and Goldblum J.R. Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol 26 (2002) 705-714
21. Kim T.W., Lee H., Kang Y.K., Choe M.S., Ryu M.H., Chang H.M., et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10 (2004) 3076-3081
22. Feakins R.M. The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 46 (2005) 270-279
23. Nakamura N., Yamamoto H., Yao T., Oda Y., Nishiyama K., Imamura M., et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36 (2005) 828-837
24. Blay P., Astudillo A., Buesa J.M., Campo E., Abad M., Garcia-Garcia J., et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10 12 Pt 1 (2004) 4089-4095
25. Singer S., Rubin B.P., Lux M.L., Chen C.J., Demetri G.D., Fletcher C.D., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20 (2002) 3898-3905
26. Van Glabbeke M., Verweij J., Casali P.G., Le Cesne A., Hohenberger P., Ray-Coquard I., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 (2005) 5795-5804
27. Goettsch W.G., Bos S.D., Breekveldt-Postma N., Casparie M., Herings R.M., and Hogendoorn P.C. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41 (2005) 2868-2872
28. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
29. Gronchi A., Casali P.G., Mariani L., Miceli R., Fiore M., Lo Vullo S., et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 23 (2005) 96-104
30. Cooper P.N., Quirke P., Hardy G.J., and Dixon M.F. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract. Am J Surg Pathol 16 (1992) 163-170
31. Hasegawa T., Matsuno Y., Shimoda T., and Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 33 (2002) 669-676
32. Antonescu C.R., Sommer G., Sarran L., Tschernyavsky S.J., Riedel E., Woodruff J.M., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
33. Lasota J., Kopczynski J., Sarlomo-Rikala M., Schneider-Stock R., Stachura T., Kordek R., et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34 (2003) 1306-1312
34. Miettinen M., Makhlouf H., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
35. Schneider-Stock R., Boltze C., Lasota J., Peters B., Corless C.L., Ruemmele P., et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11 2 Pt 1 (2005) 638-645
36. van der Zwan S.M., and DeMatteo R.P. Gastrointestinal stromal tumors: 5 years later. Cancer 104 (2005) 1781-1788
37. Van Glabbeke M., Verweij J., Casali P.G., Le Cesne A., Hohenberger P., Ray-Coquard I., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 (2005) 5795-5804
38. Van Glabbeke M., Verweij J., Casali P.G., Simens J., Le Cesne A., Reichardt P., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42 (2006) 2277-2285